ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The Asia-Pacific chronic idiopathic constipation drug market is anticipated grow at a CAGR of 5.76% during the forecast period of 2017-2025. The revenue generated by the market is expected to rise from $303.4 million in 2016 and reach $ 502.4 million by 2025.
MARKET INSIGHTS
The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. By prescription type, the over the counter drugs are more popular as they can be obtained without a doctor’s prescription. The major driver increasing the growth of the Asian market is the modern dietary habits such as intake of foods rich in animal fats especially dairy products, eggs and meat or foods that have refined sugar and low fiber. Although the market looks promising for the coming years, factors like alternate surgical treatments and the lack of awareness about such drugs in the masses are acting as restraints for market growth.
COMPETITIVE INSIGHTS
Ferring International Center S.A, Progenics Pharmaceuticals Inc Chugai Pharmaceutical, Theravance Biopharma Inc,Allergens, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, GlaxoSmithKline, Pfizer, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, , Salix Pharmaceuticals Ltd, Roche Holding Ag ,Merck Sharp & Dohme, Bayer Ag, and Sucampo Pharmaceuticals Inc, are some of the leading companies in the market.
The Asia-Pacific chronic idiopathic constipation drug market is anticipated grow at a CAGR of 5.76% during the forecast period of 2017-2025. The revenue generated by the market is expected to rise from $303.4 million in 2016 and reach $ 502.4 million by 2025.
MARKET INSIGHTS
The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. By prescription type, the over the counter drugs are more popular as they can be obtained without a doctor’s prescription. The major driver increasing the growth of the Asian market is the modern dietary habits such as intake of foods rich in animal fats especially dairy products, eggs and meat or foods that have refined sugar and low fiber. Although the market looks promising for the coming years, factors like alternate surgical treatments and the lack of awareness about such drugs in the masses are acting as restraints for market growth.
COMPETITIVE INSIGHTS
Ferring International Center S.A, Progenics Pharmaceuticals Inc Chugai Pharmaceutical, Theravance Biopharma Inc,Allergens, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, GlaxoSmithKline, Pfizer, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, , Salix Pharmaceuticals Ltd, Roche Holding Ag ,Merck Sharp & Dohme, Bayer Ag, and Sucampo Pharmaceuticals Inc, are some of the leading companies in the market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. ASIA-PACIFIC CIC DRUGS MARKET, BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. ASIA-PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. ASIA-PACIFIC CIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. ASIA-PACIFIC CIC DRUGS MARKET, BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. ASIA-PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. ASIA-PACIFIC CIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
LIST OF TABLES
TABLE 1 ASIA PACIFIC CIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 ASIA PACIFIC CIC DRUGS MARKET BY DRUG TYPE 2014-2022($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 14 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 15 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 16 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 17 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 1 ASIA PACIFIC CIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 ASIA PACIFIC CIC DRUGS MARKET BY DRUG TYPE 2014-2022($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 14 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 15 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 16 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 17 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 2 ASIA PACIFIC CIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
FIGURE 3 ASIA PACIFIC CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2016 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 APAC CIC MARKET 2017-2025 ($ MILLION)
FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 12 ASIA PACIFIC LUBIPROSTONE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 ASIA PACIFIC LINACLOTIDE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 ASIA PACIFIC OTHER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 ASIA PACIFIC PRESCRIBED CIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 16 ASIA PACIFIC OVER THE COUNTER CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 ASIA PACIFIC CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 18 CHINA CIC DRUG MARKET 2017-2027 ($ MILLION)
FIGURE 19 JAPAN CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 20 REST OF APAC CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 1 ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 2 ASIA PACIFIC CIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
FIGURE 3 ASIA PACIFIC CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2016 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 APAC CIC MARKET 2017-2025 ($ MILLION)
FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 12 ASIA PACIFIC LUBIPROSTONE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 ASIA PACIFIC LINACLOTIDE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 ASIA PACIFIC OTHER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 ASIA PACIFIC PRESCRIBED CIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 16 ASIA PACIFIC OVER THE COUNTER CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 ASIA PACIFIC CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 18 CHINA CIC DRUG MARKET 2017-2027 ($ MILLION)
FIGURE 19 JAPAN CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 20 REST OF APAC CIC DRUG MARKET 2017-2025 ($ MILLION)
